A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
A Randomized, Open-label, Controlled, Multicenter Phase III Clinical Study of SHR-A2102 for Injection Versus Investigator-selected Therapy in Locally Advanced or Metastatic Urothelial Carcinoma Previously Treated With Platinum-Containing Chemotherapy and PD-(L)1 Inhibitors and With or Without ADC
Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Listed as NCT06738251, this PHASE3 trial focuses on Advanced Urothelial Carcinoma and remains actively recruiting participants. Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd., it has been updated 3 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
3 versions recorded-
Aug 2025 — Present [monthly]
Recruiting PHASE3
-
Apr 2025 — Aug 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2025 — Apr 2025 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Hengrui Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .